All News
FDA Approves Skyrizi for Active Psoriatic Arthritis
On Friday, the U.S. Food and Drug Administration (FDA) approved risankizumab-rzaa (Skyrizi) for the treatment of adults with active psoriatic arthritis (PsA), with similar dosing in plaque psoriasis - a single 150mg subcutaneous injection four times a year after two starter doses (at weeks 0
Read Article
We are excited to announce that Dr. Janet Pope will be joining us at RheumNow Live, leading a presentation on Drug Cycling vs Switching in RA.
Join the discussion on March 19-20, on site or virtually!
https://t.co/RfWz53vem3 https://t.co/9n1UzFrkVb
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: The CDC's Advisory Committee on Immunization Practices recently recommended & approved 2 doses of the recombinant zoster vaccine for prevention of herpes zoster and complications in immunodeficient/immunosuppressed adults aged ≥19 years.
https://t.co/VlA5BIyrZG https://t.co/VjBHtCNq37
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: UCB announced positive top-line results from Phase 3 BE COMPLETE study, bimekizumab, in active psoriatic arthritis, who failed TNFi. Bimekizumab pts showed a 50% ACR50 at week 16, as well as signif improvements in PASI90, MDA, PGA https://t.co/HhVdIhqHoL
Links:
Dr. John Cush RheumNow ( View Tweet)
FREED study (asympt hyperuricemic without gout) showed febuxostat x 24 mos dint alter carotid atherosclerosis, but at 3 years, (Substudy of 1004 pts), showed FEB signif lowered risk of CVA, CV, renal renal events and death (vs PBO) https://t.co/BS4wiIaYZv
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Dr. Jack Cush reviews the news and journal articles from this past week on https://t.co/V10S4oVFsv. These reports are about better outcomes in Lupus; fewer Gout flares with T2T and the power of belief.
https://t.co/8sxDTiU9QD https://t.co/bc8A1FWkVS
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Network metanalysis (28 RCTs, 12 504 pts) of Biologics & small molecules therapy in active ulcerative colitis. Upadacitinib 45 mg qd ranked 1st (RR 0.73) vs PBO, infliximab 5 mg/kg & 10 mg/kg ranked 2nd & 3rd. UPA > TNFi at remission. https://t.co/ne6yfBEJJz
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: FDA has approved 2 JAK inhibitors for use in severe atopic dermatitis (eczema) - Abbvies upadacitinib (Rinvoq) and Pfizers abrocitinib (Cibinqo). https://t.co/6wdyN6NvVa https://t.co/RfliRSH5Kf
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Annals of Internal Medicine describes a propensity matched comparison study of risedronate and alendronate, showing that, compared to alendronate, risedronate drug holidays were associated with a small increase in risk for hip fractures.
https://t.co/6qnMUzqV3E https://t.co/iIrahEuB09
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/q9TvLjtY9p
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/KsnQxYXHkI
Links:
Dr. John Cush RheumNow ( View Tweet)
UCB announced positive top-line results from Phase 3 BE COMPLETE study, bimekizumab, in active psoriatic arthritis, who failed TNFi. Bimekizumab pts showed a 50% ACR50 at week 16, as well as signif improvements in PASI90, MDA, PGA https://t.co/pnhQKeUxKt
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR 2021 Highlights: Comorbidities in axSpA Presentation
Sponsored by Novartis Medical Affairs
Tune into Dr Marina Magrey discuss axSpA comorbidities focusing on cardiovascular manifestations.
https://t.co/w1EnRapTaN https://t.co/v5ZDmpUq1b
Links:
Dr. John Cush RheumNow ( View Tweet)
3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients
https://t.co/UXUryaQ7Fz https://t.co/p40xND4lVP
Links:
Dr. John Cush RheumNow ( View Tweet)
The CDC's Advisory Committee on Immunization Practices recently recommended & approved 2 doses of the recombinant zoster vaccine for prevention of herpes zoster and complications in immunodeficient/immunosuppressed adults aged ≥19 years.
https://t.co/nk4feoUO5B https://t.co/6fR33fG5xw
Links:
Dr. John Cush RheumNow ( View Tweet)
791 knee OA pts studied for progression after steroid (GC) (n=629) vs hyaluronic (HA) injxn (n=162). Knee OA progression was similar between groups for JSN (RR 1.00) & K/L grade (1.03); but IA GC had slightly lower TKR (HR 0.75 [CI 0.51–1.09]) https://t.co/74eg2Zvdy1 https://t.co/soXb7bdq6O
Links:
Dr. John Cush RheumNow ( View Tweet)
Yesterdays RheumNow Live Vote survey of 170 Rheumatologists, showed that 74-80% of Rheums are reporting shortages of IV tocilizumab (Actemra) -- TCZ listed by FDA site as a drug in shortage largely due to demand, Genentech says there is supply https://t.co/YAvR4vbVHV
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live Vote survey of 159 Rheumatologists shows, because of the Actemra Shortage, Rheums are either changing to subQ TCZ (45%), changing to other biologic or tsDMARD (33%) or waiting for resupply of TCZ (21%). https://t.co/zNeyRsYClD @CreakyJoints https://t.co/aGYO2fqw7J
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live vote Survey of 161 Rheums shows that in addition to a tocilizumab shortage the main drug shortage is for sulfasalazine (34%) https://t.co/uE856PbF2v @CreakyJoints https://t.co/eCLy3rpjoI
Links:
Dr. John Cush RheumNow ( View Tweet)
GWAS study in RA used to develop polygenic risk score (PRS) for Xray progression (training set = 500 and validated testing set= 740). Risk factors for severe XRAY progr = PRS (P=0.00019), female (P=0.0033), ACPA (P=0.0023), BMI (P=0.031) https://t.co/dwDSnTFUqs
Links:
Dr. John Cush RheumNow ( View Tweet)